What BBB does

BBB, operating as MARK-B Inc., is a South Korean-domiciled medical diagnostics company that has developed a point-of-care immunoassay analyzer. The company's flagship product, the MARK-B™ Analyzer, is a fully automated device built around its patented MESIA (Magnetic Electrochemical Sandwich ImmunoAssay) technology. The analyzer processes whole blood, serum, or plasma samples and delivers quantitative biomarker results in minutes without requiring sample pre-processing, addressing the clinical need for lab-quality diagnostics at the point of care. A broad test menu is offered across tumor markers (AFP, PSA, CEA, CA19-9, CA125), cardiovascular disease (cTnI, CK-MB, Myoglobin, D-dimer, hsCRP, NT-proBNP, Galectin-3, ST2), sepsis (PCT, IL-6, CRP), infectious diseases (COVID-19, Influenza A&B), thyroid function (TSH, T3, T4), metabolism (Vitamin D, Ferritin), and Alzheimer's disease screening (β-amyloid, τ protein, NfL), though several major panels remain marked 'Not available for sale' on the company website.

The company targets hospitals, clinics, and medical laboratories through an enterprise field sales motion, with distribution likely routed through medical device channels globally. Revenue is generated via hardware sales of the analyzer combined with recurring consumable cartridge sales. The platform supports connectivity via Wi-Fi, Bluetooth, and USB, and integrates with hospital Data Management Systems through POCT1-A2, HL7, and FHIR protocols. The company has raised approximately $21.8M in disclosed funding across rounds from 2010-2018, including strategic pharma participation from Dongwha Pharm, and operates with a 11-50 person team across its South Korean headquarters and a Mountain View, California office. CEO Jaekyu Choi leads the company alongside a mixed Korean and US-based executive team.

Several execution signals warrant caution. No revenue, regulatory clearances (FDA, CE, or MFDS), or specific customer accounts are disclosed. Multiple test panels are explicitly listed as 'Not available for sale'. The last funding round was in October 2018, with no subsequent raises documented. The company's original marketing positioning ('turn your living room into doctor's office') diverges from the more detailed product specifications that describe enterprise hospital integration, suggesting possible unresolved product-market fit or positioning ambiguity.

Name

BBB

Legal name

MARK-B Inc.

Website

https://bbbtech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

MARK-B Inc. (BBB) is a South Korean medical diagnostics company that builds the MARK-B™ point-of-care immunoassay analyzer using patented MESIA technology, serving hospitals, clinics, and medical laboratories with rapid quantitative biomarker testing across multiple disease categories.

Ownership category

akta.pro rank

Product category

Point-of-care diagnostic devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

akta.pro secondary industries

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Point-of-care diagnostics
• Immunoassay analyzers
• Medical diagnostic devices
• Biomarker testing
• Electrochemical diagnostics

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Instrument Sales: MARK-B Inc. sells the BBB diagnostic instrument system along with consumable test cartridges for point-of-care testing. Revenue generated from hardware sales of analyzers and proprietary test consumables.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

BBB develops and sells the MARK-B™ Analyzer, a point-of-care diagnostic system based on patented MESIA (Magnetic Electrochemical Sandwich ImmunoAssay) technology that delivers lab-quality quantitative biomarker results from whole blood, serum, or plasma in minutes without manual pre-processing. The system is sold alongside a proprietary menu of single-use test cartridges spanning tumor markers, cardiovascular disease, sepsis, infectious disease, thyroid, metabolism, and Alzheimer's panels, plus accessories such as thermal printers and barcode scanners.

Product overview

MARK-B Inc. offers a single unified product platform: the MARK-B™ Analyzer, a fully automated point-of-care diagnostic system. The system utilizes MESIA (Magnetic Electrochemical Sandwich ImmunoAssay), a patented technology, to deliver lab-quality results from whole blood, serum, or plasma samples in minutes without pre-processing. The analyzer is offered with multiple optional test panel modules covering tumor markers (AFP, PSA, CEA, CA19-9, CA125), cardiovascular disease (cTnI, CK-MB, Myoglobin, D-dimer, hsCRP, NT-proBNP, Galectin-3, ST2), sepsis (PCT, IL-6, CRP), infectious diseases (COVID-19, Influenza A&B), thyroid (TSH, T3, T4), metabolism (Vitamin D, Ferritin), and Alzheimer's disease (β-amyloid, τ protein, NfL). Optional accessories include a thermal printer and barcode scanner. Connectivity is provided via cloud server, Wi-Fi, Bluetooth, and USB ports with support for POCT1-A2, HL7, and FHIR protocols.

Differentiator

Problem solved

Functional benefit

Brands

• MARK-B: Company brand name for medical diagnostic instruments and test systems including the BBB electrochemical immunoassay analyzer.
• MESIA

Products and services

• MARK-B™ Analyzer A compact point-of-care immunoassay analyzer based on patented MESIA (Magnetic Electrochemical Sandwich ImmunoAssay) technology that delivers lab-quality quantitative biomarker results from whole blood, serum, or plasma in minutes without manual pre-processing. Runs Android 7.0 software with onboard QC, RFID-coded cartridge recognition, and cloud/LIS connectivity via POCT1-A2, HL7, and FHIR. Intended for hospitals, clinics, urgent care centers, and clinical laboratories.
• Tumor Marker Test Cartridges Proprietary single-use test cartridges that run tumor marker biomarker panels on the MARK-B™ Analyzer, designed for quantitative oncology-related testing at the point of care.
• Cardiovascular Disease Test Cartridges Proprietary single-use test cartridges for cardiovascular disease biomarker testing (e.g., cardiac markers) run on the MARK-B™ Analyzer at the point of care.
• Sepsis Test Cartridges Proprietary single-use test cartridges for sepsis-related biomarker testing on the MARK-B™ Analyzer, supporting rapid diagnosis in emergency and critical care settings.
• Infectious Disease Test Cartridges Proprietary single-use test cartridges for infectious disease biomarker testing on the MARK-B™ Analyzer at the point of care.
• Thyroid Test Cartridges Proprietary single-use test cartridges for thyroid function biomarker testing on the MARK-B™ Analyzer at the point of care.
• Metabolism Test Cartridges Proprietary single-use test cartridges for metabolism biomarker testing on the MARK-B™ Analyzer at the point of care.
• Alzheimer's Disease Test Cartridges Proprietary single-use test cartridges for Alzheimer's disease biomarker testing on the MARK-B™ Analyzer at the point of care.
• Analyzer Accessories (Thermal Printer, Barcode Scanner) Supporting hardware accessories including thermal printers and barcode scanners used with the MARK-B™ Analyzer in clinical point-of-care workflows.

Quantifiable outcome

• Results delivered in minutes
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature4 records

Partnerships

One partnership is on record.

• Analytica Chimica Acta (Elsevier)coreStrategic or Co-development Partner · 1 March 2019Research collaboration resulting in publication of MESIA technology validation in peer-reviewed journal Analytica Chimica Acta. This scientific publication establishes the clinical validity and accuracy of MARK-B's core diagnostic technology.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• SD Biosensor: South Korea-based POC immunoassay and rapid diagnostic test manufacturer with overlapping product categories (cardiac markers, infectious disease). Operates as a direct regional competitor to MARK-B in Korean and global hospital POC markets.
• Boditech Med: Korean IVD company specializing in POC immunoassay analyzers (AFS, ichroma) with similar cardiovascular, infectious disease, and tumor marker menus. Closest head-to-head competitor in the Korean hospital POC segment.
• QuidelOrtho: US-listed POC diagnostics specialist (Triage MeterPro, Sofia) with strong cardiovascular and infectious disease franchises. Comparable in offering immunoassay-based POC tests for similar hospital and clinic customers.
• RADIOMETER (Danaher): Specialist in blood gas and POC immunoassay testing (ABL90, AQT90), serving hospital critical care with rapid diagnostic systems. Comparable business model of proprietary instrument + consumable cartridge sold to hospital labs and ICUs.

Broad incumbents

• Abbott Diagnostics (i-STAT / Alinity): Global IVD leader with i-STAT handheld POC analyzer and Alinity hospital system. Provides broad POC and central lab immunoassay menus including cardiac, sepsis, and infectious disease — directly overlaps with MARK-B's test portfolio at much larger scale.
• Roche Diagnostics (cobas): World's largest IVD manufacturer offering cobas analyzer family including cardiac POC (cobas h 232) and central lab immunoassay systems. Represents the dominant incumbent that hospitals already use, against which MARK-B must compete for incremental POC placements.
• Siemens Healthineers (Atellica / epoc): Global IVD incumbent with Atellica central lab and epoc blood gas/immunoassay POC system. Competes for the same hospital POC budget and features comparable connectivity (HL7/FHIR) and multi-analyte menus.
• Bio-Rad Laboratories: US-based life science and clinical diagnostics company with specialty immunoassay and quality control product lines. Overlaps with MARK-B in biomarker assay development and clinical chemistry controls for hospital labs.

Emerging players

• EKF Diagnostics: UK-listed POC diagnostics company with focus on hemoglobin, HbA1c, and small immunoassay analyzers. Comparable as a smaller specialist POC vendor targeting primary care and clinic channels.
• GenBody Inc. Korean emerging IVD company known for COVID-19 rapid antigen tests expanding into immunoassay analyzers. Comparable as a Korean-based POC diagnostics peer targeting infectious disease and broader hospital markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bbb_tech
• Facebookfacebook.com/bbbtechnologies
• LinkedInlinkedin.com/company/bbbinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BBB